We treated different indications, more than 10 patients with miv-cel in neuroimmunological diseases, and we see overall in the different indications that they respond unexpectedly well to this treatment. We see a robust expansion of the cells, of the CAR T-cells, and we see also a robust B-cell depletion. In view of the responses, because we have very different indications, we see the response also very different in the scores which are normally used for these different indications, for example, Stiff Person syndrome, but also a few patients in myasthenic diseases see a very good response in, for example, MGADL...
We treated different indications, more than 10 patients with miv-cel in neuroimmunological diseases, and we see overall in the different indications that they respond unexpectedly well to this treatment. We see a robust expansion of the cells, of the CAR T-cells, and we see also a robust B-cell depletion. In view of the responses, because we have very different indications, we see the response also very different in the scores which are normally used for these different indications, for example, Stiff Person syndrome, but also a few patients in myasthenic diseases see a very good response in, for example, MGADL. That’s much more in the first data than we expected from the other modern treatments which are approved, like FCNR modulation or complement inhibition. So that’s a very promising first result. In view of safety, we see no ICANS in our whole cohort. We see a very manageable CRS, a low grade 1 to 2. And in the long term, that’s the open question. We see some neutropenic patients, but no very severe infections. So overall, very manageable side effects.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
